Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

Cancer Investigation

Volumn 26, Issue 5, 2008, Pages 491-498

  Papadimitriou, Christos A ^a,e   Papakostas, Pavlos ^b   Timotheadou, Eleni ^c   Aravantinos, Gerasimos ^d   Bamias, Aristotelis ^a   Fountzilas, George ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d AGII ANARGIRI CANCER HOSPITAL   (Greece)

^e Hellenic Cooperative Oncology Group   (Greece)

Author keywords

Adjuvent chemotherapy; Breast cancer; CMF; Epirubicin; Weekly paclitaxel

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIMETINDENE; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; RANITIDINE; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROENTERITIS; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MOOD DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; SKIN PRURITUS; SUICIDAL IDEATION; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; GREECE; HUMANS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 45949105633     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701829785     Document Type: Article

References (35)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365, 1687-1717.
2. Norton, L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. The Oncologist 2001, 6 (Suppl 3), 30-35.
3. Citron, M.L. Dose density in adjuvant chemotherapy for breast cancer. Cancer Invest 2004, 22, 555-568.
4. Colozza, M.; de Azambuja, E.; Cardoso, F.; Bernard, C.; Piccart M.J. Breast Cancer: achievements in adjuvant systemic therapies in the pre-genomic era. The Oncologist 2006, 11, 111-125.
5. Henderson, I.C.; Berry, D.A.; Demetri, G.D.; Cirrincione, C.T.; Goldstein, L.J.; Martino, S.; Ingle, J.N.; Cooper, M.R.; Hayes, D.F.; Tkaczuk, K.H.; Fleming, G.; Holland, J.F.; Duggan, D.B.; Carpenter, J.T.; Frei, E., 3rd; Schilsky, R.L.; Wood, W.C.; Muss, H.B.; Norton, L. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21, 976-983.
6. Hudis, C.; Citron, M.; Berry, D.; Cirrincione, C.; Gradishar, W.; Davidson, N.; Martino, S.; Livingston, R.; Ingle, J.; Perez, E.; Abrams, J.; Schilsky, R.; Ellis, M.; Muss, H.; Norton, L.; Winer E. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005, Abstract 41.
7. Mamounas, E.P.; Bryant, J.; Lembersky, B.; Fehrenbacher, L.; Sedlacek, S.M.; Fisher, B.; Wickerham, D.L.; Yothers, G.; Soran, A.; Wolmark, N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23, 3686-3696.
8. Crown, J.P.; Francis, P.; Di Leo, A.; Buyse, M.; Balil, A.; Anderson, M.; Nordenskj̈old, B.; Jakesz, R.; Gutierrez J.; Piccart M. Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 Trial at 5 years median follow-up (MFU). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: LBA519
9. Fountzilas, G.; Skarlos, D.; Dafni, U.; Gogas, H.; Briasoulis, E.; Pectasides, D.; Papadimitriou, C.; Markopoulos, C.; Polychronis, A.; Kalofonos, H.P.; Siafaka, V.; Kosmidis, P.; Timotheadou, E.; Tsavdaridis, D.; Bafaloukos, D.; Papakostas, P.; Razis, E.; Makrantonakis, P.; Aravantinos, G.; Christodoulou, C.; Dimopoulos, A.M. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005, 16, 1762-1771.
10. Eniu, A.; Palmieri, F.M.; Perez, E.A. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. The Oncologist 2005, 10, 665-685.
11. Seidman, A.D.; Hudis, C.A.; Albanell, J.; Tong, W.; Tepler, I.; Currie, V.; Moynahan, M.E.; Theodoulou, M.; Gollub, M.; Baselga, J.; Norton, L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998, 16, 3353-3361.
12. Wist, E.A.; Sommer, H.H.; Ostenstad, B.; Risberg, T.; Fjaestad, K. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004, 43, 11-14.
13. Sato, K.; Inoue, K.; Saito, T.; Kai, T.; Mihara, H.; Okubo, K.; Koh, J.; Mochizuki, H.; Tabei, T. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). Jpn J Clin Oncol 2003, 33, 371-376.
14. Gori, S.; Mosconi, A.M.; Basurtol, C.; Cherubinil, R.; De Angelis, V.; Tonato, M.; Colozza, M. Weekly paclitaxel in metastatic breast cancer patients: a phase II study. Tumori 2002, 88, 470-473.
15. Perez, E.A.; Vogel, C.L.; Irwin, D.H.; Kirshner, J.J.; Patel, R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001, 19, 4216-4223.
16. Perez, E.A.; Vogel, C.L.; Irwin, D.H.; Kirshner, J.J.; Patel, R.Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 2002, 73, 85-88.
17. Seidman, A.D.; Berry, D.; Cirrincione, C.; Harris, L.; Dressler, L.; Muss, H.; Naughton, M.; Norton, L.; Winer, E.; Hudis, C. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004, 22 (Suppl), 14S (abstract 512).
18. Sparano, J.A.; Wang, M.; Martino, S.; Jones, V.; Perez, E.A.; Saphner, T.; Wolff, A.C.; Sledge, G.W.; Wood, W.C.; Davidson, N.E. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. 28th Annual San Antonio Breast Cancer Symposium 2005. Breast Cancer Res Treat 2005, 94 (Suppl 1) (abstract 48).
19. Fountzilas, G.; Pectasides, D.; Christodoulou, C.; Timotheadou, E.; Economopoulos, T.; Papakostas, P.; Papadimitriou, C.; Gogas, H.; Efstratiou, I.; Skarlos, D. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol 2006, 23, 479-488.
20. Goldhirsch, A.; Glick, J.H.; Gelber, R.D.; Coates, A.S.; Thurlimann, B.; Senn, H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005, 16, 1569-1583.
21. Hryniuk, W.; Levine, M.N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986, 4, 1162-70.
22. Hryniuk, W.M.; Levine, M.N.; Levin, L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1986, 1, 87-94.
23. Von Hoff, D.D.; Clark, G.M.; Weiss, G.R.; Marshall, M.H.; Buchok, J.B.; Knight, W.A. 3rd; LeMaistre, C.F. Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 1986, 4, 1827-34.
24. Fisher, B.; Anderson, S.; Wickerham, D.L.; DeCillis, A.; Dimitrov, N.; Mamounas, E.; Wolmark, N.; Pugh, R.; Atkins, J.N.; Meyers, F.J.; Abramson, N.; Wolter, J.; Bornstein, R.S.; Levy, L.; Romond, E.H, Caggiano, V.; Grimaldi, M.; Jochimsen, P.; Deckers, P. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997, 15, 1858-69.
25. Fisher, B.; Anderson, S.; DeCillis, A.; Dimitrov, N.; Atkins, J.N.; Fehrenbacher, L.; Henry, P.H.; Romond, E.H.; Lanier, K.S.; Davila, E.; Kardinal, C.G.; Laufman, L.; Pierce, H.I.; Abramson, N.; Keller, A.M.; Hamm, J.T.; Wickerham, D.L.; Begovic, M.; Tan-Chiu, E.; Tian, W.; Wolmark, N. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999, 17, 3374-88.
26. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19(3), 602-11.
27. Fornier, M.N.; Seidman, A.D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C.; Panageas, K.S.; Atienza, M.; Norton, L.; Hudis, C. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clin Cancer Res 2007, 13, 223-7.
28. Dang, C.T.; D'Andrea, G.M.; Moynahan, M.E.; Dickler, M.N.; Seidman, A.D.; Fornier, M.; Robson, M.E.; Theodoulou, M.; Lake, D.; Currie, V.E.; Hurria, A.; Panageas, K.S.; Norton, L.; Hudis, C.A. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004, 10, 5754-61.
29. Tabernero, J.; Climent, M.A.; Lluch, A.; Albanell, J.; Vermorken, J.B.; Barnadas, A.; Anton, A.; Laurent, C.; Mayordomo, J.I.; Estaun, N.; Losa, I.; Guillem, V.; Garcia-Conde, J.; Tisaire, J.L.; Baselga, J. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004, 15, 1358-65.
30. Crown, J.; O'Leary, M.; Ooi, W.S. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. The Oncologist 2004, 9 (Suppl 2), 24-32.
31. Esteva, F.J.; Valero, V.; Booser, D.; Guerra, L.T.; Murray, J.L.; Pusztai, L.; Cristofanilli, M.; Arun, B.; Esmaeli, B.; Fritsche, H.A.; Sneige, N.; Smith, T.L.; Hortobagyi, G.N. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20, 1800-8.
32. Seidman, A.D.; Hudis, C.A.; Albanell, J.; Tong, W.; Tepler, I.; Currie, V.; Moynahan, M.E.; Theodoulou, M.; Gollub, M.; Baselga, J.; Norton, L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998, 16, 3353-61.
33. Anan, K.; Mitsuyama, S.; Taniguchi, H.; Yamamoto, Y.; Fujiyoshi, K.; Tateishi, T.; Tamura, K. Adjuvant doxorubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study in a variety of practice settings in Kyushu. Gan To Kagaku Ryoho 2006, 33, 1417-22.
34. Green, M.C.; Buzdar, A.U.; Smith, T.; Ibrahim, N.K.; Valero, V.; Rosales, M.F.; Christofanilli, M.; Booser, D.J.; Pusztai, L.; Rivera, E.; Theriault, R.L.; Carter, C.; Frye, D.; Hunt, K.K.; Symmans, W.F.; Strom, E.A.; Sahin, A.A.; Sikov, W.; Hortobagyi, G.N. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005, 23, 5873-5874.
35. Ellis, G.K.; Green, S.J.; Russell, C.A.; Royce, M.E.; Perez, E.A.; Livingston. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant treatment for inflammatory and locally advanced breast cancer. J Clin Oncol 2006, 24 (Suppl): 18S (abstract LBA537).